1. Home
  2. BEAM vs QURE Comparison

BEAM vs QURE Comparison

Compare BEAM & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

N/A

Current Price

$23.08

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Logo uniQure N.V.

QURE

uniQure N.V.

N/A

Current Price

$24.11

Market Cap

3.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BEAM
QURE
Founded
2017
1998
Country
United States
Netherlands
Employees
N/A
248
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
BEAM
QURE
Price
$23.08
$24.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
13
Target Price
$49.85
★ $59.78
AVG Volume (30 Days)
★ 1.8M
1.7M
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.31
29.67
EPS
N/A
★ N/A
Revenue
$24,000.00
★ $13,107,000.00
Revenue This Year
N/A
$44.21
Revenue Next Year
N/A
$398.45
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 33.33
N/A
52 Week Low
$20.23
$8.73
52 Week High
$38.26
$51.72

Technical Indicators

Market Signals
Indicator
BEAM
QURE
Relative Strength Index (RSI) 40.33 46.32
Support Level $22.65 $20.63
Resistance Level $28.19 $26.01
Average True Range (ATR) 1.92 1.93
MACD -0.33 0.68
Stochastic Oscillator 0.07 57.62

Price Performance

Historical Comparison
BEAM
QURE

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Share on Social Networks: